Cargando…

Six-Month Response to Delamanid Treatment in MDR TB Patients

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hewison, Cathy, Ferlazzo, Gabriella, Avaliani, Zaza, Hayrapetyan, Armen, Jonckheere, Sylvie, Khaidarkhanova, Zarema, Mohr, Erika, Sinha, Animesh, Skrahina, Alena, Vambe, Debrah, Vasilyeva, Irina, Lachenal, Nathalie, Varaine, Francis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2017
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621551/ https://www.ncbi.nlm.nih.gov/pubmed/28767036 http://dx.doi.org/10.3201/eid2310.170468

Ejemplares similares

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Does optimized adherence support improve treatment outcomes in RR / MDR-TB patients on 18–20 months regimen in Tbilisi, Georgia?
por: Jomidava, Tinatin, et al.
Publicado: (2021)

Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB
por: Taneja, R., et al.
Publicado: (2023)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

‘Z(S)-MDR-TB' versus ‘Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility
por: Zhang, Ying, et al.
Publicado: (2012)

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa
por: Mohr, Erika, et al.
Publicado: (2018)

MDR TB Transmission, Singapore
por: Chee, Cynthia B.E., et al.
Publicado: (2013)

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
por: Sweeney, Sedona, et al.
Publicado: (2020)

Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs( )
por: Huerga, Helena, et al.
Publicado: (2022)

Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
por: Franke, Molly F., et al.
Publicado: (2021)

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
por: Lee, Myungsun, et al.
Publicado: (2019)

Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar
por: Wai, Pyae Phyo, et al.
Publicado: (2018)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Management of MDR-TB: Review of Iran's Experience
por: Masjedi, Mohammad Reza, et al.
Publicado: (2013)

MDR-TB in Pakistan: Challenges, efforts, and recommendations
por: Khan, Mahad Ahmed, et al.
Publicado: (2022)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
por: Mbuagbaw, Lawrence, et al.
Publicado: (2019)

Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting
por: Mitnick, Carole D, et al.
Publicado: (2015)

High prevalence of infection and low incidence of disease in child contacts of patients with drug-resistant tuberculosis: a prospective cohort study
por: Huerga, Helena, et al.
Publicado: (2019)

Heightened Vulnerability to MDR-TB Epidemics after Controlling Drug-Susceptible TB
por: Bishai, Jason D., et al.
Publicado: (2010)

The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
por: Harichander, Sheetal, et al.
Publicado: (2022)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
por: Achar, Jay, et al.
Publicado: (2017)

Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia
por: Mehari, Kibriti, et al.
Publicado: (2019)

The role of delamanid in the treatment of drug-resistant tuberculosis
por: Lewis, Joseph M, et al.
Publicado: (2015)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Why has MDR-TB prevalence increased in Iran?
por: Heidary, Mohsen, et al.
Publicado: (2016)

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
por: Ali, Monadil H., et al.
Publicado: (2019)

Fluoroquinolone preventive therapy for children exposed to MDR-TB
por: Gureva, T., et al.
Publicado: (2022)

Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
por: Al-Mutairi, Noura M., et al.
Publicado: (2019)

Analysis of multi drug resistant tuberculosis (MDR-TB) financial protection policy: MDR-TB health insurance schemes, in Chhattisgarh state, India
por: Kundu, Debashish, et al.
Publicado: (2018)

Collaborative public–private initiatives targeting multidrug-resistant tuberculosis (MDR-TB) supported by the Lilly MDR-TB Partnership: experiences in 2012–2016
por: Shelby, Peter W, et al.
Publicado: (2017)

759. Molecular Characterization and Epidemiology of Multidrug-Resistant Mycobacterium tuberculosis (MDR-TB) and Identification of Possible Cases of Local Transmission of MDR-TB in Kuwait
por: Mokaddas, Eiman, et al.
Publicado: (2018)

Correction: The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
por: Harichander, Sheetal, et al.
Publicado: (2022)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Correction to: Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
por: Al-Mutairi, Noura M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3507tnq65d7r863j5g11fivqbg